The tumor-suppressor TP53 is mutated in about 50% of NSCLC12, 13 and in several other human cancers11; therefore, we investigated whether restoration of functional TP53 expression could revert the oncogenic effects of uc.339. This evidence concerns the gene TP53 and neoplasm.